CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Price, Quote, News and Overview
TSX:CPH - Toronto Stock Exchange - CA17253X1050 - Common Stock - Currency: CAD
CPH.CA Quote, Performance and Key Statistics
TSX:CPH (5/23/2025, 7:00:00 PM)
12.42
-0.03 (-0.24%)
The current stock price of CPH.CA is 12.42 CAD. In the past month the price increased by 3.5%. In the past year, price increased by 43.09%.
CPH.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.17 | 2.26B | ||
| CRON.CA | CRONOS GROUP INC | 15.5 | 1.08B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 5.82 | 711.76M | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 615.32M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | 115.8 | 576.86M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 527.43M | ||
| ACB.CA | AURORA CANNABIS INC | 32.78 | 413.64M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 366.74M | ||
| HITI.CA | HIGH TIDE INC | N/A | 255.28M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 250.36M | ||
| TSND.CA | TERRASCEND CORP | N/A | 198.39M | ||
| HLS.CA | HLS THERAPEUTICS INC | N/A | 148.03M |
Related stock screener links
About CPH.CA
Company Profile
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. The company also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.
Company Info
CIPHER PHARMACEUTICALS INC
5750 Explorer Drive,, Suite 404
Mississauga ONTARIO L6H 0M2 CA
CEO: Craig Mull
Employees: 9
Phone: 19056025840
CIPHER PHARMACEUTICALS INC / CPH.CA FAQ
What is the stock price of CIPHER PHARMACEUTICALS INC today?
The current stock price of CPH.CA is 12.42 CAD. The price decreased by -0.24% in the last trading session.
What is the ticker symbol for CIPHER PHARMACEUTICALS INC stock?
The exchange symbol of CIPHER PHARMACEUTICALS INC is CPH and it is listed on the Toronto Stock Exchange exchange.
On which exchange is CPH.CA stock listed?
CPH.CA stock is listed on the Toronto Stock Exchange exchange.
What is the price forecast or stock price prediction for CIPHER PHARMACEUTICALS INC stock?
9 analysts have analysed CPH.CA and the average price target is 17.05 CAD. This implies a price increase of 37.31% is expected in the next year compared to the current price of 12.42. Check the CIPHER PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CIPHER PHARMACEUTICALS INC worth?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a market capitalization of 318.20M CAD. This makes CPH.CA a Small Cap stock.
How many employees does CIPHER PHARMACEUTICALS INC have?
CIPHER PHARMACEUTICALS INC (CPH.CA) currently has 9 employees.
What are the support and resistance levels for CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
CIPHER PHARMACEUTICALS INC (CPH.CA) has a support level at 11.56 and a resistance level at 12.43. Check the full technical report for a detailed analysis of CPH.CA support and resistance levels.
Is CIPHER PHARMACEUTICALS INC (CPH.CA) expected to grow?
The Revenue of CIPHER PHARMACEUTICALS INC (CPH.CA) is expected to grow by 56.92% in the next year. Check the estimates tab for more information on the CPH.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CIPHER PHARMACEUTICALS INC (CPH.CA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CPH.CA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CPH.CA, evaluating the profitability, health, valuation and growth aspects
- CIPHER PHARMACEUTICALS INC (CPH.CA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CIPHER PHARMACEUTICALS INC (CPH.CA) Sales and EPS estimates to see what analysts future expectations are.
- CIPHER PHARMACEUTICALS INC (CPH.CA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CIPHER PHARMACEUTICALS INC (CPH.CA) Insider and Institutional Ownership to learn about the owners and their transactions.
- CIPHER PHARMACEUTICALS INC (CPH.CA) Stock Chart to make your own analysis
- CIPHER PHARMACEUTICALS INC (CPH.CA) Latest news and press-releases to stay up to date.
Does CIPHER PHARMACEUTICALS INC (CPH.CA) stock pay dividends?
CPH.CA does not pay a dividend.
What is the Price/Earnings (PE) ratio of CIPHER PHARMACEUTICALS INC (CPH.CA)?
The PE ratio for CIPHER PHARMACEUTICALS INC (CPH.CA) is 19.41. This is based on the reported non-GAAP earnings per share of 0.64 and the current share price of 12.42 CAD. Check the full fundamental report for a full analysis of the valuation metrics for CPH.CA.
CPH.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CPH.CA. When comparing the yearly performance of all stocks, CPH.CA is one of the better performing stocks in the market, outperforming 82.8% of all stocks.
CPH.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to CPH.CA. While CPH.CA has a great profitability rating, there are some minor concerns on its financial health.
CPH.CA Financial Highlights
Over the last trailing twelve months CPH.CA reported a non-GAAP Earnings per Share(EPS) of 0.64. The EPS decreased by -41.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 34.6% | ||
| ROA | 7.1% | ||
| ROE | 11.28% | ||
| Debt/Equity | 0.39 |
CPH.CA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to CPH.CA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 40.28% and a revenue growth 56.92% for CPH.CA